"I love Takeda Vaccines"

2022-05-07 21:56:00

Terms of UsePrivacy Notice Maps & Facts Who We Are Pipeline Newsroom Leadership Takeda Careers Terms of Use Privacy Notice Follow usTerms of UsePrivacy Notice Better Health, Brighter Future Better Health, Brighter Future Press Release: Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results Read more DENGUE Endemic in over Endemic in 100 Countries[3] over 100 Countries[3] ZIKA 86 Countries now show evidence OF ZIKA VIRUS INFECTION[2] now show evidence OFZIKA VIRUS INFECTION[2] NOROVIRUS ­estimated $60.3 BILLION­estimated $60.3 BILLION ANNUAL ECONOMIC IMPACT WORLDWIDE[2] ANNUAL ECONOMIC IMPACT WORLDWIDE[2] Scroll THE NUMBERS ARE CHANGING THE NUMBERS ARE CHANGING Take a closer look at worldwide infectious disease facts and statistics. Take a closer look at worldwide infectious disease facts and statistics. Dengue Zika Norovirus Map shows areas at risk for dengue transmission. Map shows areas that have or have had Zika transmission. Map shows areas with the risk of norovirus transmission. Dengue facts About 50% of the world's population lives under the threat of dengue, which is responsible for approximately 390 million infections globally per year.[3] Dengue facts Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries.[3] Zika facts As of July 2018, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.[1] Zika facts As of March 2017, a decline in cases of Zika infection has been reported in some countries, or in some parts of countries; WHO advises that vigilance needs to remain high.[1] Norovirus facts Norovirus is the most common viral cause of acute gastroenteritis worldwide, responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis.[2] Norovirus facts Norovirus is estimated to cause more than 699 million illness cases each year.[2] Interested inLearning More?For updated disease information and statistics, please visit the following websites: World Health Organization Centers for Disease Control and Prevention Back to disease facts and statistics vaccines change numbers If all children wereimmunizedwith existingvaccines, by 2020we wouldsave nearly25,000,000livesIf all children were immunized withexisting vaccines,by 2020 we wouldsave nearly25,000,000 lives[6] Estimated2-3 MILLIONdeaths averted each year withimmunizationfrom diphtheria, tetanus,pertussis (whooping cough), and measlesEstimated 2-3 MILLIONdeaths averted each year withimmunizationfrom diphtheria, tetanus, pertussis (whooping cough), and measles [7] vaccines change lives infectious diseases that need our attention infectious diseases that need our attention Learn about some of the diseases we are focusing on. Learn about some of the diseases we are focusing on. DENGUE About the disease Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.[3] ZIKA About the disease: Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.[1] NOROVIRUS About the disease: Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.[8] DENGUE About the disease Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.[3] ZIKA About the disease: Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.[1] NOROVIRUS About the disease: Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.[8] We're workingto turn thingsaround#LetsTurnDengueAround#LetsTurnZikaAround#LetsTurnNorovirusAround We're working toturn things around WHO WE ARE WHO WE ARE OUR VISION OUR VISION To protect the health of people everywhere through vaccines that address the most important infectious diseases. OUR MISSION OUR MISSION To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world. OUR VALUES OUR VALUES In our day-to-day work, we focus on the following values while upholding the highest ethical standards:FairnessHonestyIntegrityPerseverence OUR PRODUCTS OUR PRODUCTS OUR PRODUCTS MARKETED IN JAPANBLB-750 (H5N1 Flu)Measles RubellaMumpsDiphtheria Tetanus ToxoidSeasonal Flu (Denka & Kaketsuken)Varicella (Biken)Japanese Encephalitis (Biken) OUR VISION To protect the health of people everywhere through vaccines that address the most important infectious diseases. OUR MISSION To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world. OUR VALUES In our day-to-day work, we focus on the following values while upholding the highest ethical standards:FairnessHonestyIntegrityPerseverence OUR PRODUCTS OUR PRODUCTS MARKETED IN JAPANBLB-750 (H5N1 Flu)Measles RubellaMumpsDiphtheria Tetanus ToxoidSeasonal Flu (Denka & Kaketsuken)Varicella (Biken)Japanese Encephalitis (Biken) WE'RE COMMITTED TO A HEALTHIER FUTURE WE'RE COMMITTED TO A HEALTHIER FUTURE Here's what we are working on: Here's what we are working on: View Clinical Trials DENGUE Takeda's vaccine candidate: A live attenuated tetravalent dengue vaccine is being developed.Development Phase: Phase 3 NOROVIRUS Takeda's vaccine candidate: A virus-like particle vaccine for two norovirus genotypes is being developed.Development Phase: Phase 2b ZIKA Takeda's vaccine candidate: An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).Development Phase: Phase 1 View Clinical Trials DENGUE Takeda's vaccine candidate: A live attenuated tetravalent dengue vaccine is being developed.Development Phase: Phase 3 NOROVIRUS Takeda's vaccine candidate: A virus-like particle vaccine for two norovirus genotypes is being developed.Development Phase: Phase 2b ZIKA Takeda's vaccine candidate: An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).Development Phase: Phase 1 We are working toexpandThe life-savingimpact ofvaccinesaround the world we are working toexpand The life-savingimpact of vaccinesaround the world NEWSROOM NEWSROOM: WE'RE MAKING PROGRESS Takeda is taking steps towards making an impact on public health by developing innovative new vaccines. Takeda is taking steps towards making an impact on public health by developing innovative new vaccines. Visit the Takeda Vaccines Newsroom for news releases, videos and infographics. Swipe to see the five most recent press releases from the Takeda Vaccine Business. Click the arrows to see the five most recent press releases from the Takeda Vaccine Business. April 19, 2022 Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan Read the full story Read the full story September 07, 2021 Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan Read the full story Read the full story July 29, 2021 Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate Read the full story Read the full story July 20, 2021 Takeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Government Read the full story Read the full story May 22, 2021 Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results Read the full story Read the full story May 21, 2021 Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan Read the full story Read the full story March 25, 2021 Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EUand Dengue-Endemic Countries Read the full story Read the full story leading the way leading the way Meet the people who are committed to making change. Meet the people who are committed to making change. Our team is working passionately toward improving public health.Click to meet our leaders Swipe to meet our leaders Explore Takeda Careers Gary Dubin, MD President, Takeda Vaccine Business Gary is President of the Takeda Vaccine Business. He joined Takeda in 2015 and led the Global Medical Office before assuming his current role in 2022. Gary has more than 30 years of experience in vaccine research. Before joining Takeda, he spent the previous 20 years at GSK Vaccines. Joseph Santangelo, PhD Head of Global CMC Joe is Head of Global CMC for the Takeda Vaccine Business. He is a biotech entrepreneur who previously started two vaccine development companies, Microscience and SingVax (later merged with Inviragen and acquired by Takeda Vaccines in May 2013). Joe has more than 35 years of research and technology experience in cell biology, infectious diseases and industrial microbiology. Rogerio Ribeiro Head of Commercial Rogerio is Head of Commercial for the Takeda Vaccine Business. Before joining Takeda, Rogerio spent more than 20 years at GSK, holding various leadership positions includingSenior Vice President and Head of Global Health Unit, Head of Emerging Markets Region, and Senior Vice President & Area Head, Latin America. Tom Hensey, MSc MBA Head of Commercial Manufacturing & Supply Tom is the Head of Commercial Manufacturing & Supply for the Takeda Vaccine Business, and joined Takeda in 2016. His prior experience in vaccines includes strategy and operations roles at Novartis and Seqirus.He previously worked at McKinsey & Co. in the US and Japan, and in engineering roles at Merck. Amy Atwood Head of Vaccine Communications Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid. Kay Oishi Head of Human Resources Kay is the Head of Human Resources for the Takeda Vaccine Business. He joined Takeda in 2006 and worked in Takeda’s R&D organization before joining the Vaccine business. Kay has more than 20 years of HR experience, and worked at NEC Corporation prior to Takeda. Rupa Cornell, JD Head Counsel Rupa is Head Counsel for the Takeda Vaccine Business. She has been practicing law for over 20 years. Prior to joining Takeda, Rupa held legal positions with increasing responsibilities at various biotech companies including Stealth BioTherapeutics, Sage Therapeutics, Biogen and Boston Scientific Corporation. Anita Rehberger Head of Global Vaccine Quality Anita is Head of Global Vaccine Quality for the Takeda Vaccine Business. She joined Takeda in 2017. Anita has more than 20 years of Quality Management and Quality Control industry experience with vaccine, recombinant and plasma- derived product development and commercial supply from her time at Baxter and Pfizer. Fabien Jolly Head of Data, Digital & Technology Fabien is Head of Data, Digital and Technology for the Takeda Vaccine Business. He joined Takeda in 2017. Fabien has more than 20 years of experience in managing global Information Technology organizations in the biopharmaceutical industry from his time at Shire and Sanofi Aventis where he worked closely with the Sanofi Pasteur vaccines division. Inge LeFevre, MD Head of Vaccine Development Inge is Head of Vaccine Development for the Takeda Vaccine Business. She joined Takeda in 2017 and most recently has served as Head of Global Regulatory Affairs, Vaccines. Inge has more than 20 years of experience in Clinical Development, Regulatory Affairs and Pharmacovigilance across all global markets and stages of vaccine development. Prior to joining Takeda, Inge worked at GSK Vaccines. Dieter Gniel Head of Global Medical Affairs Dieter is Head of Global Medical Affairs for the Takeda Vaccine Business. He joined Takeda in 2014. Prior to Takeda, Dieter has held global and regional medical affairs roles at Novartis Vaccines and Chiron Vaccines. Andrea Bertolotti-Ciarlet, PhD Head of Vaccine Research and Analytics Andrea is Head of Vaccine Research and Analytics for the Takeda Vaccine Business. Prior to joining Takeda in 2016, she worked at Merck and Biogen. Andrea has more than 20 years of experience in research, drug discovery and development. Matt Symonds Chief Financial Officer Matt is the Chief Financial Officer for the Takeda Vaccine Business. He joined Takeda in 2011 and has held various global financial leadership roles across the company. Matt has more than 20 years of experience in the industry, including his prior role as an investment banker focused in biopharma. Explore Takeda Careers Our team is working passionately toward improving public health. Swipe to meet our leaders Gary Dubin, MD President, Takeda Vaccine Business Gary is President of the Takeda Vaccine Business. He joined Takeda in 2015 and led the Global Medical Office before assuming his current role in 2022. Gary has more than 30 years of experience in vaccine research. Before joining Takeda, he spent the previous 20 years at GSK Vaccines. Joseph Santangelo, PhD Head of Global CMC Joe is Head of Global CMC for the Takeda Vaccine Business. He is a biotech entrepreneur who previously started two vaccine development companies, Microscience and SingVax (later merged with Inviragen and acquired by Takeda Vaccines in May 2013). Joe has more than 35 years of research and technology experience in cell biology, infectious diseases and industrial microbiology. Rogerio Ribeiro Head of Commercial Rogerio is Head of Commercial for the Takeda Vaccine Business. Before joining Takeda, Rogerio spent more than 20 years at GSK, holding various leadership positions includingSenior Vice President and Head of Global Health Unit, Head of Emerging Markets Region, and Senior Vice President & Area Head, Latin America. Tom Hensey, MSc MBA Head of Commercial Manufacturing & Supply Tom is the Head of Commercial Manufacturing & Supply for the Takeda Vaccine Business, and joined Takeda in 2016. His prior experience in vaccines includes strategy and operations roles at Novartis and Seqirus.He previously worked at McKinsey & Co. in the US and Japan, and in engineering roles at Merck. Amy Atwood Head of Vaccine Communications Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid. Kay Oishi Head of Human Resources Kay is the Head of Human Resources for the Takeda Vaccine Business. He joined Takeda in 2006 and worked in Takeda’s R&D organization before joining the Vaccine business. Kay has more than 20 years of HR experience, and worked at NEC Corporation prior to Takeda. Rupa Cornell, JD Head Counsel Rupa is Head Counsel for the Takeda Vaccine Business. She has been practicing law for over 20 years. Prior to joining Takeda, Rupa held legal positions with increasing responsibilities at various biotech companies including Stealth BioTherapeutics, Sage Therapeutics, Biogen and Boston Scientific Corporation. Anita Rehberger Head of Global Vaccine Quality Anita is Head of Global Vaccine Quality for the Takeda Vaccine Business. She joined Takeda in 2017. Anita has more than 20 years of Quality Management and Quality Control industry experience with vaccine, recombinant and plasma- derived product development and commercial supply from her time at Baxter and Pfizer. Fabien Jolly Head of Data, Digital & Technology Fabien is Head of Data, Digital and Technology for the Takeda Vaccine Business. He joined Takeda in 2017. Fabien has more than 20 years of experience in managing global Information Technology organizations in the biopharmaceutical industry from his time at Shire and Sanofi Aventis where he worked closely with the Sanofi Pasteur vaccines division. Inge LeFevre, MD Head of Vaccine Development Inge is Head of Vaccine Development for the Takeda Vaccine Business. She joined Takeda in 2017 and most recently has served as Head of Global Regulatory Affairs, Vaccines. Inge has more than 20 years of experience in Clinical Development, Regulatory Affairs and Pharmacovigilance across all global markets and stages of vaccine development. Prior to joining Takeda, Inge worked at GSK Vaccines. Dieter Gniel Head of Global Medical Affairs Dieter is Head of Global Medical Affairs for the Takeda Vaccine Business. He joined Takeda in 2014. Prior to Takeda, Dieter has held global and regional medical affairs roles at Novartis Vaccines and Chiron Vaccines. Andrea Bertolotti-Ciarlet, PhD Head of Vaccine Research and Analytics Andrea is Head of Vaccine Research and Analytics for the Takeda Vaccine Business. Prior to joining Takeda in 2016, she worked at Merck and Biogen. Andrea has more than 20 years of experience in research, drug discovery and development. Matt Symonds Chief Financial Officer Matt is the Chief Financial Officer for the Takeda Vaccine Business. He joined Takeda in 2011 and has held various global financial leadership roles across the company. Matt has more than 20 years of experience in the industry, including his prior role as an investment banker focused in biopharma. 1World It's the single thing that that connects us all Stay Connected @TakedaPharma .news-room-slide .readmore a {margin-right: -31px;}@media (max-width: 767px){.numbersContent .videoCTA { margin-top: 123px;}} Connect with us: TERMS OF USE Privacy Notice Takeda.com References TERMS OF USE Privacy Notice Takeda.com References Connect with us: Copyright 1995-2020 Takeda Pharmaceutical Company Limited. All rights reserved. × YOU ARE ABOUT TO LEAVE THIS WEBSITE AND ENTER A WEBSITE OPERATED BY AN INDEPENDENT THIRD PARTYThe links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities on those websites will be governed by the policies and practices of those third parties.Please select "Continue" if you wish to be taken to this third-party website. CANCEL CONTINUE